Abstract: The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin-4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amytrophic lateral sclerosis (ALS), anxiety and depression.

Abstract: The invention relates to novel fredericamycin derivatives, to medicaments containing these derivatives or salts thereof, and to the use of fredericamycin derivatives for treating diseases, particularly tumor diseases.

Abstract: The invention provides novel, substituted 7-arylamino[1,2,4]triazolo[4,3-a]pyridine compounds Formula (I): pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10 R11, R12, R13, R14 and L are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

Abstract: The invention provides novel, substituted 4-arylamino pyridone compounds (formula (I)), pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R 1, R2, R9, R 10, R 11, R 12, R 13, R 14 and L are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

Abstract: The invention relates to novel fredericamycin derivatives of general formula (Ia) or (Ib), to medicaments containing the fredericamycin derivatives or salts thereof, and to the use of the fredericamycin derivatives for treating diseases, especially tumor diseases.

Abstract: A method and apparatus are disclosed for adjusting the bandwidth of a connection between at least two communication endpoints in a data network via a monitoring unit and a control unit. The connection in the data network is assigned at least one transmission channel for data transmission. The user data is, in this case, allocated to at least one communication connection; in particular a voice connection. The monitoring unit monitors the signaling connection for requests for at least one further communication connection; in particular, a voice connection. When a request occurs, it signals to the control unit to assign to the connection one or more additional free transmission channels for the at least one requested communication connection.

Abstract: The invention relates to novel fredericamycin derivatives, to drugs containing said derivatives or the salts thereof, and to the use of the fredericamycin derivatives for treating diseases, especially cancer diseases.

Abstract: The invention relates to novel fredericamycin derivatives of general formula (Ia) or (Ib), to medicaments containing said derivatives or the salts of the same, and to the use of said fredericamycin derivatives for treating diseases, especially tumour diseases.

Abstract: A method and system for transmitting data between two communication devices via a packet-oriented communication network, wherein the communication devices are, in each case, connected to the packet-oriented communication network via a conversion device. Time-slot-oriented signaling and user information allocated to a connection between the communication devices are separated at the transmitter end by the conversion devices. The signaling information is then transmitted transparently via a first link via the packet-oriented communication network. The user information is converted into a data format supported by the packet-oriented communication network for transmission via the packet-oriented communication network and is then transmitted via a second connection. Finally, the user information is converted back at the receiver end and joined together with the signaling information.

Abstract: The invention relates to novel Fredericamycin derivatives, to medicaments containing these derivatives or salts thereof, and to the use of Fredericamycin derivatives for treating diseases, particularly tumor diseases.

Abstract: A method and apparatus are disclosed for adjusting the bandwidth of a connection between at least two communication endpoints in a data network via a monitoring unit and a control unit. The connection in the data network is assigned at least one transmission channel for data transmission. The user data is, in this case, allocated to at least one communication connection; in particular a voice connection. The monitoring unit monitors the signaling connection for requests for at least one further communication connection; in particular, a voice connection. When a request occurs, it signals to the control unit to assign to the connection one or more additional free transmission channels for the at least one requested communication connection.

Abstract: A method and system for transmitting data between two communication devices via a packet-oriented communication network, wherein the communication devices are, in each case, connected to the packet-oriented communication network via a conversion device. Time-slot-oriented signaling and user information allocated to a connection between the communication devices are separated at the transmitter end by the conversion devices. The signaling information is then transmitted transparently via a first link via the packet-oriented communication network. The user information is converted into a data format supported by the packet-oriented communication network for transmission via the packet-oriented communication network and is then transmitted via a second connection. Finally, the user information is converted back at the receiver end and joined together with the signaling information.

Abstract: ISDN basic interface S.sub.o of an ISDN communication system that can be connected to an S.sub.o interface of an ISDN communication terminal equipment or of an ISDN terminal of a public communication network (ISDN-PSTN) is provided. For automatic recognition and commissioning of such an ISDN terminal, this is first initialized as one of the possible connection modes and the processes of layer 1 and layer 2 are activated in interaction with the administration and maintenance and dependability processes. When it occurs from the message traffic of the individual components that a commissioning is not possible, then the appertaining S.sub.o terminal is initiated with the next connection mode and the commissioning is restarted. The controller previously made the corresponding, new configuring data available. After a successful commissioning, the S.sub.

Abstract: There is now provided a solvent cement having a total of less than 80 weight percent of solvents and a thermoplastic polyurethane elastomer as at least one of the resins dissolved in the solvent. The solvent mixture contains at least a 5- or 6-membered water miscible lactone or lactam such as N-methyl-2-pyrrolidone (NMP) in an amount of 21 weight percent or less based on the weight of all the ingredients. The reduced solvent concentration assists in lowering VOC emissions while preserving the hydrostatic burst strength mechanical property required by ASTM D 2564-88.

Abstract: There is now provided a solvent cement having a total of less than 80 weight percent of solvents and a thermoplastic polyurethane elastomer as at least one of the resins dissolved in the solvent. The solvent mixture contains at least a 5- or 6-membered water miscible lactone or lactam such as N-methyl-2-pyrrolidone (NMP) in an amount of 21 weight percent or less based on the weight of all the ingredients. The reduced solvent concentration assists in lowering VOC emissions while preserving the hydrostatic burst strength mechanical property required by ASTM D 2564-88.

Abstract: In thermoplastic elastomers selected from the group consisting of the thermoplastic polyurethanes, of the polyetheresters and of the polyetheramides which are derived from polyetherpolycarbonatediols as diol components, the polyetherpolycarbonatediols used are reaction products of phosgene, dialkyl carbonates having C.sub.1 -C.sub.4 -alkyl groups or cyclic carbonates having C.sub.2 -C.sub.4 -alkylene bridges or mixtures thereof with mixtures ofa.sub.1) from 10 to 100 mol % of polyoxytetramethylenediol having a number average molecular weight M.sub.n of from 150 to 500 anda.sub.2) from 0 to 90 mol % of polyoxyalkylenediols which differ from a.sub.1) and have C.sub.2 -C.sub.8 -alkylene groups, aliphatic alkanediols of 2 to 14 carbon atoms, alicyclic alkanediols of 3 to 14 carbon atoms or alkylene oxides of 2 or 3 carbon atoms, or mixtures thereof.

Abstract: A process for the preparation of a polyurethane elastomer by reactinga) an organic and/or modified organic polyisocyanate withb) at least one relatively high-molecular-weight polyoxybutylene-polyoxyalkylene glycol from the group comprising polyoxybutylene-polyoxyethylene glycols, polyoxybutylene-polyoxypropylene glycols and/or polyoxybutylene-polyoxpropylene-polyoxyethylene glycols,c) at least one chain extender and/or crosslinking agent andd) at least one glycidyl compound containing units having the structure ##STR1## in which n is a number from 1 to 6,X is an alkylene, arylene, --O-- or --N-- bridge, andR.sup.1 and R.sub.2 are identical or different and are hydrogen, methyl or ethyl,in the presence or absence ofe) blowing agents,f) catalysts andg) assistants and/or additives,and mixtures of polyoxybutylene-polyoxyalkylene glycols (b) and glycidyl compounds (d).

Abstract: Polyetherpolycarbonatediols are composed essentially ofA) from 3 to 63.7 mol % of units derived from a polyoxytetramethylenediol,B) from 63.7 to 3 mol % of units derived from a polyoxy-C.sub.2 -C.sub.8 -alkylenediol other than A), an aliphatic alkanediol of from 2 to 14 carbon atoms, an alicyclic alkanediol of from 3 to 14 carbon atoms or an alkylene oxide of 2 to 3 carbon atoms, or a mixture thereof, andC) from 33.3 to 50 mol % of units derived from phosgene, a dialkyl carbonate having C.sub.1 -C.sub.4 -alkyl groups or a cyclic carbonate having C.sub.2 -C.sub.4 -alkylene bridges, or a mixture thereof.